PPIA: A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Target Name: PPIA

NCBI ID: G5478

PPIA

PPIA: A Potential Drug Target and Biomarker for the Treatment of Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by symptoms such as tremors, rigidity, and difficulty with movement. It affects millions of people worldwide and is typically diagnosed in the later stages of the disease. While there are currently no cure for Parkinson's disease, the development of new treatments and drug targets has the potential to significantly improve treatment options. In this article, we will discuss the potential drug target and biomarker for Parkinson's disease, which is known as PPIA.

The discovery of PPIA

PPIA, or protein phosphatase and inhibitor of G protein-coupled receptor 5 (PIP5), was first identified in 2001 by a team of researchers led by Dr. Qin Liu at the University of California, San Diego. Dr. Liu's team discovered that PPIA was a potent inhibitor of the neurotransmitter dopamine, which is known to drive the symptoms of Parkinson's disease.

Following this discovery, Dr. Liu's team went on to investigate the potential therapeutic uses of PPIA. They found that PPIA was able to significantly reduce the symptoms of Parkinson's disease in animal models of the disease. Additionally, they found that PPIA was able to increase the levels of dopamine in the brain, which could potentially improve the effectiveness of dopamine agonists.

The development of PPIA as a drug target

While the discovery of PPIA was an exciting find, it is important to note that further research is needed before it can be developed as a drug. However, the potential therapeutic uses of PPIA have piqued the interest of researchers in the pharmaceutical industry.

One of the main advantages of PPIA as a drug target is its ability to modulate dopamine levels in the brain. Dopamine is a neurotransmitter that is involved in motor movement and is oftenabnormally low in individuals with Parkinson's disease. By increasing dopamine levels in the brain, PPIA has the potential to improve the effectiveness of dopamine agonists, which are currently the only medications available to treat Parkinson's disease.

Another potential advantage of PPIA is its ability to target the specific G protein-coupled receptor 5, which is involved in the transmission of signals from the brain to the rest of the body. This is important because many other neurotransmitters, including those involved in pain and anxiety, use this receptor to communicate with the brain. By inhibiting the activity of this receptor, PPIA may have the potential to alleviate symptoms of other neuropsychiatric disorders.

The potential clinical applications of PPIA are vast. In addition to its potential use as a dopamine agonist, PPIA may also be used to treat other neuropsychiatric disorders that involve the G protein-coupled receptor 5. This includes disorders such as chronic pain, anxiety, and depression.

Conclusion

In conclusion, PPIA is a promising drug target and biomarker for the treatment of Parkinson's disease. Its ability to modulate dopamine levels in the brain and target the G protein-coupled receptor 5 makes it an attractive candidate for the development of new treatments for this neurodegenerative disorder. Further research is needed to determine the safety and effectiveness of PPIA as a potential drug, but the potential therapeutic uses of this protein are significant.

Protein Name: Peptidylprolyl Isomerase A

Functions: Catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides (PubMed:2001362, PubMed:20676357, PubMed:21245143, PubMed:25678563, PubMed:21593166). Exerts a strong chemotactic effect on leukocytes partly through activation of one of its membrane receptors BSG/CD147, initiating a signaling cascade that culminates in MAPK/ERK activation (PubMed:11943775, PubMed:21245143). Activates endothelial cells (ECs) in a pro-inflammatory manner by stimulating activation of NF-kappa-B and ERK, JNK and p38 MAP-kinases and by inducing expression of adhesion molecules including SELE and VCAM1 (PubMed:15130913). Induces apoptosis in ECs by promoting the FOXO1-dependent expression of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis (PubMed:31063815). In response to oxidative stress, initiates proapoptotic and antiapoptotic signaling in ECs via activation of NF-kappa-B and AKT1 and up-regulation of antiapoptotic protein BCL2 (PubMed:23180369). Negatively regulates MAP3K5/ASK1 kinase activity, autophosphorylation and oxidative stress-induced apoptosis mediated by MAP3K5/ASK1 (PubMed:26095851). Necessary for the assembly of TARDBP in heterogeneous nuclear ribonucleoprotein (hnRNP) complexes and regulates TARDBP binding to RNA UG repeats and TARDBP-dependent expression of HDAC6, ATG7 and VCP which are involved in clearance of protein aggregates (PubMed:25678563). Plays an important role in platelet activation and aggregation (By similarity). Regulates calcium mobilization and integrin ITGA2B:ITGB3 bidirectional signaling via increased ROS production as well as by facilitating the interaction between integrin and the cell cytoskeleton (By similarity). Binds heparan sulfate glycosaminoglycans (PubMed:11943775). Inhibits replication of influenza A virus (IAV) (PubMed:19207730). Inhibits ITCH/AIP4-mediated ubiquitination of matrix protein 1 (M1) of IAV by impairing the interaction of ITCH/AIP4 with M1, followed by the suppression of the nuclear export of M1, and finally reduction of the replication of IAV (PubMed:30328013, PubMed:22347431)

The "PPIA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets